Phreesia, Inc. (NYSE:PHR) Receives $29.12 Consensus Target Price from Analysts

Shares of Phreesia, Inc. (NYSE:PHR) have been given a consensus recommendation of “Moderate Buy” by the nineteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seventeen have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $29.1176.

Several research firms have recently weighed in on PHR. Wells Fargo & Company initiated coverage on shares of Phreesia in a research report on Thursday, January 8th. They set an “overweight” rating and a $30.00 price objective for the company. Royal Bank Of Canada initiated coverage on shares of Phreesia in a report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 target price on the stock. Zacks Research cut shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Truist Financial set a $24.00 price target on Phreesia in a report on Thursday, January 8th. Finally, DA Davidson lowered their price objective on Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, January 23rd.

Phreesia Stock Performance

NYSE:PHR opened at $11.77 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. Phreesia has a fifty-two week low of $10.75 and a fifty-two week high of $32.76. The company has a 50 day simple moving average of $13.02 and a two-hundred day simple moving average of $18.22. The company has a market capitalization of $709.34 million, a PE ratio of -117.65 and a beta of 0.67.

Insider Buying and Selling at Phreesia

In other Phreesia news, SVP Amy Beth Vanduyn sold 2,202 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $36,024.72. Following the transaction, the senior vice president directly owned 157,349 shares in the company, valued at approximately $2,574,229.64. This represents a 1.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Allison C. Hoffman sold 3,995 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $65,358.20. Following the sale, the general counsel directly owned 169,661 shares of the company’s stock, valued at approximately $2,775,653.96. This trade represents a 2.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 60,353 shares of company stock valued at $1,006,528 over the last ninety days. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PHR. Federated Hermes Inc. acquired a new stake in Phreesia in the third quarter worth $32,000. Van ECK Associates Corp raised its holdings in shares of Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock valued at $42,000 after purchasing an additional 1,102 shares during the period. Asset Management One Co. Ltd. acquired a new position in shares of Phreesia during the third quarter valued at about $45,000. Rockefeller Capital Management L.P. boosted its position in shares of Phreesia by 354.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock worth $47,000 after purchasing an additional 2,149 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of Phreesia by 83.4% during the 4th quarter. KBC Group NV now owns 3,449 shares of the company’s stock worth $58,000 after purchasing an additional 1,568 shares in the last quarter. 92.10% of the stock is owned by institutional investors.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.